Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beinaglutide vs Glargine in T2DM Glycemic Variability
NCT03829891Completed
- Sponsor
- Xijing Hospital
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of beinaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Xijing Hospital. Primary endpoints: The proportion and rate of the fasting blood glucose control at 16 weeks, Proportion of patients with glycosylated hemoglobin < 7% at 16 weeks and 1 more. Started Aug 2018; status: completed.
02
Drugs
beinaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03829891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829891.